Advances in pharmacological treatment of migraine

Bibliography

• TFELT-HANSEN P: Drug treatment of migraine: acute treatment and migraine prophylaxis. Cum: Opirr. Neural (1996) 9:211–213.
   PubMed Web of Science ®Google Scholar
• TFELT-HANSEN P: Preliminary analysis of randomized placebo-controlled clinical trials with newer 5-HT1D receptor agonists for the treatment of migraine attacks. In Headache Treatment: Trial Methodology and New Drugs. J Olesen & P Tfelt-Hansen (Eds.) Lippincott-Raven, New York, USA (1997).
   Google Scholar
• TFELT-HANSEN E BLOCK G, DAHLOF C et al FOR THE INTERNATIONAL HEADACHE SOCIETY CLINICAL TRIALS SUBCOMMITTEE: Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia (2000) 20:765–786.
   PubMed Web of Science ®Google Scholar
• ••The guidelines for the design of drug trialsin the treatment of acute migraine attacks and the prevention of migraine is helpfull when evaluating the quality of published trials.
   Google Scholar
• GOADSBY PJ, FERRARI M, LIPTON RB. Migraine: current understanding and management. N Engl. I Med. (2001) 343. (In press).
   Google Scholar
• TFELT-HANSEN P: Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on numbers needed to treat. Cephalalgia (1998) 18:532–538.
   PubMed Web of Science ®Google Scholar
• ••A very competent metaanalysis of thesumatriptan trials with numbers neede to treat and net gain
   Google Scholar
• PFAFFENRATH V, CUNIN G, SJONELL G, PRENDERGAST S: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache (1998) 38:184–190.
   PubMed Web of Science ®Google Scholar
• WILKINSON M, PFAFFENRATH V, SCHOENEN J, DIENER HC, STEINER T: Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia (1995) 15:337–357.
   PubMed Web of Science ®Google Scholar
• PERRY CM, MARKHAM A: Sumatriptan. An updated review of its use in migraine. Drugs (1998) 55:889–922.
   Google Scholar
• MOORE K, HUSSEY E, SHAW S, FUSEAU E, DUQUESNOY C, PAKES G: Safety, tolerability and pharmacokinetics of sumatriptan in healthy subjects following ascending intranasal doses and multiple intransal doses. Cephalalgia (1997) 17:541–550.
   PubMed Web of Science ®Google Scholar
• BECKER WJ, ON BEHALF OF THE STUDY GROUP: A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalalgia (1995) 15\(Suppl. 14):271–276.
   Google Scholar
• RYAN R, ELKIND A, BAKER CC, MULLICAN W, DEBUSSY S, ASGHARNEJAD M: Sumatriptan nasal spray for the acute treatment of migraine. Neurology (1997) 49:1225–1230.
   PubMed Web of Science ®Google Scholar
• ASHFORD E, SALONEN R, SAIERS J, WOESSNER M: Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia (1998) 18:273–277.
   PubMed Web of Science ®Google Scholar
• DIAMOND S, ELKIND A, JACKSON RT, RYAN R, DEBUSSEY S, ASGHARNEJAD M: Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch. Family Med. (1998) 7:234–240.
   PubMedGoogle Scholar
• DIENER HC: Sumatriptan - Therapy. In:Drug Treatment of Miine and Other Headaches. HC Diener (Ed.). Basel, Karger, Switzerland (2000).
   Google Scholar
• GOBEL H, ON BEHALF OF THE STUDY GROUP: A placebo-controlled, dose defining study of sumatriptan suppositories in the acute treatment of migraine. Cephalalgia (1995) 15\(Suppl. 14):232.
   Google Scholar
• TEPPER SJ, COCHRAN A, HOBBS S, WOESSNER M, ON THE BEHALF OF THE 52B351 STUDY GROUP: Sumatriptan suppositories for the acute treatment of migraine. Int. I Clin. Pract. (1998) 52:31–35.
   PubMed Web of Science ®Google Scholar
• HAMALAINEN ML, HOPPU K, SANTAVUORI P: Sumatriptan for migraine attacks in children: A randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? Neurology (1997) 48:1100–1103.
   Google Scholar
• OBERALL MA, WENZEL D: Intranasal sumatriptan for the acute treatment of migraine in children. Neurology (1999) 52:1507–1510.
   PubMed Web of Science ®Google Scholar
• JOFFE RT, SOKOLOV ST. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr. Scam/. (1997) 95:551–552.
   PubMed Web of Science ®Google Scholar
• FREITAG FG, DIAMOND S, DIAMOND M, URBAN G, PEPPER B: Subcutaneous sumatriptan in patients treated with monoamine oxidase inhibitors and other prophylactic agents. Headache Quarterly (1998) 9:165–171.
   Web of Science ®Google Scholar
• O'CONNOR P, GLADSTONE P: Oralsumatriptan-associated transmural myocardial infarction. Neurology (1995) 45:2274–2276.
   PubMed Web of Science ®Google Scholar
• MAIN ML, RAMASWAMY K, ANDREWS TC: Cardiac arrest and myocardial infarction immediately after sumatriptan injection (letter). Ann. Internal Med. (1998) 128:874.
   PubMed Web of Science ®Google Scholar
• OTTERVANGER JP, PAALMAN HJA, BOXMA GL, STRICKER BHC: Transmural myocardial infarction with sumatriptan. Lancet (1993) 341:861–862.
   PubMed Web of Science ®Google Scholar
• MUELLER L, GALLAGHER RIVI, CIERVO CA: Vasospasm-induced myocardial infarction with sumatriptan. Headache (1996) 36:329–331.
   PubMed Web of Science ®Google Scholar
• OTTERVANGER JP, STRICKER BHC: Cardiovascular adverse reactions to sumatriptan - cause for concern? CNS Dugs (1995) 3:90–98.
   Web of Science ®Google Scholar
• CAVAZOS JE, CAREES JB, CHILUKURI VR. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet (1994) 343:1105–1106.
   PubMed Web of Science ®Google Scholar
• LUMAN W, GRAY RS. Adverse reactionsassociated with sumatriptan. Lancet (1993) 341:1091–1092.
   PubMed Web of Science ®Google Scholar
• JAYAMAHA JEL, STREET MK: Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med(1995) 21:82–83.
   PubMed Web of Science ®Google Scholar
• KNUDSEN JF, FRIEDMAN B, CHEN M, GOLD WASSER JE: Ischemic colitis and sumatriptan use. Arch. Internal. Med. (1998) 158:1946–1948.
   PubMed Web of Science ®Google Scholar
• WELCH KMA, MATHEW NT, STONE P, ROSAMOND W, SAIERS J, GUTTERMAN D: Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia (2000) 20:687–695.
   PubMed Web of Science ®Google Scholar
• O'QUINN S, DAVIS R, GUTTERMANN D, PAIT G, FOX A: Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine. Cephalalgia (1999) 19:223–231.
   PubMed Web of Science ®Google Scholar
• LEWIS PJ, BARRINGTON SF, MARSDEN PK, MAISEY MN, LEWIS LD: A study of the effects of sumatriptan on myocardial perfusion in healthy male migraineurs using 13NH3 positron emission tomography. Cephalalgia (1997) 48:1542–1550.
   Google Scholar
• SHUHAIBER S, PASTUSZAK A, SCHICK B, MATSUI D, SPIVEY G, BROCHU J, KOREN G: Pregnancy outcome following first trimester exposure to sumatriptan. Neurology (1998) 51:581–583.
   PubMed Web of Science ®Google Scholar
• OLESEN C, STEFFENSEN FH, SORENSEN HT, NIELSEN GL, OLSEN J: Pregnancy outcome following prescription for sumatriptan. Headache (2000) 40:20–24.
   PubMed Web of Science ®Google Scholar
• O'QUINN S, EPHROSS SA, WILLIAMS V, DAVIS RL, GUTTERMAN DL, FOX AW: Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch. Cyrrecol. Obstet. (1999) 263:7–12.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN J, DAHLOF CGH, DIENER HC et al. ON BEHALF OF THE SUBCUTANEOUS ALNIDITAN STUDY G. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia (1996) 16:497–502.
   Google Scholar
• COUCH JR, SAPER J, MELOCHE JP, FOR THE NORTH AMERICAN BMS STUDY GROUP Treatment of migraine with BMS 180048: response at 2 hours. Headache (1996) 36:523–530.
   PubMedGoogle Scholar
• RYAN RE, ELKIND A, GOLDSTEIN J: Twenty-four-hour effictiveness of BMS 180048 in the acute treatment of migraine headaches. Headache (1997) 37:245–248.
   PubMed Web of Science ®Google Scholar
• KLASSEN A, ELKIND A, ASHARNEJAD M, WEBSTER C, LAURENZA A, ON BEHALF OF THE NARATRIPTAN 52WA3001 STUDY GROUP: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache (1997) 37:630–645.
   Google Scholar
• MATHEW NT, ASGHARNEJAD M, PEYKAMIAN M, LAURENZA A, ON BEHALF OF THE NARATRIPTAN 52WA3001 STUDY GROUP: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology (1997) 49:1485–1490.
   Google Scholar
• CONNOR HE, FENIUK W, BEATTIE DT et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia (1997) 17:145–152.
   PubMed Web of Science ®Google Scholar
• GUNASEKARA NS, WISEMAN LR. Naratriptan. CNS Drugs (1997) 8:402–408.
   Web of Science ®Google Scholar
• GOADSBY PJ. A triptan too far? J. Neural. Neurosurg. Psychiatry (1998) 64:143–147.
   PubMed Web of Science ®Google Scholar
• •A nice review of the triptans until 1998.
   Google Scholar
• SALONEN R. Naratriptan. mt. I CM]. Pict. (1999) 53:552–556.
   Google Scholar
• DAHLOF C, HOGENHUIS L, OLESEN J et al.: Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Europ. j Neural. (1998) 5:469–477.
   PubMed Web of Science ®Google Scholar
• HEYWOOD J, BOMHOF MAM, PRADALIER A, THAVENTHIRAN L, WINTER P, HASSANI H: Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia (2000) 20:470–474.
   PubMed Web of Science ®Google Scholar
• KEMPSFORD RD, LACEY LF, KEENE ON: The safety, tolerability and pharmacokinetics of subcutaneous GR 85548, a novel 5-HT1-receptor agonist for the treatment of migraine. Br Pharmacy]. (1993) 36:170.
   Google Scholar
• SHEFTELL F, 0 'QUINN S, WATSON C, PAIT D, WINTER P: Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache (2000) 40:103–110.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, KNIGHT YE: Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia (1997) 17:153–158.
   PubMed Web of Science ®Google Scholar
• FERRARI MD: 311C90: Increasing the options for the therapy with effective acute antimigraine 5HT1B/D receptor agonists. Neurology (1997) 48\(Suppl. 3):21–24.
   Google Scholar
• RAPOPORT AM, RAMADAN NM, ADELMANN JU et al. ON BEHALF OF THE 017 CLINICAL TRIAL STUDY GROUP: Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study. Neurology (1997) 49:1210–1218.
   Google Scholar
• DAHLOF C, DIENER HC, GOADSBY PJ et al.: Zolmitriptan, a 5-HT1B/D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur. j Neural. (1998) 5:535–543.
   PubMed Web of Science ®Google Scholar
• GERAUD G, OLESEN J, PFAFFENRATH V et al. ON BEHALF OF THE STUDY GROUP: Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia (2000) 20:30–38.
   PubMed Web of Science ®Google Scholar
• SOLOMON GD, CADE RK, KLAPPER JA, EARL NL, SAPER JR, RAMADAN NM, ON BEHALF OF THE 042 CLINICAL TRIAL STUDY GROUP: Clinical efficacy and tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine. Neurology (1997) 49:1219–1225.
   PubMed Web of Science ®Google Scholar
• SCHOENEN J, SAWYER J: Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia (1997) 17\(Suppl. 18):28–40.
   Google Scholar
• THE INTERNATIONAL 311C90 LONG-TERM STUDY GROUP: The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache (1998) 38:173–183.
   Google Scholar
• BECKER WJ, LEE D: Zolmitriptan nasal spray is effective, fast-acting and well tolerated during both, short- and long-term treatment. Cephalalgia (2001) 21:271.
   Google Scholar
• EDMEADS JG, MILLSON DS: Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. Cephalalgia (1997) 17:41–52.
   PubMed Web of Science ®Google Scholar
• ROLAN P: Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig (R), 311C90). Cephalalgia (1997) 17\(Suppl. 18):21–27.
   Google Scholar
• PECK RW, SEABER EJ, DIXON R et al.: The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br. J. Chi]. Pharmacy] (1997) 44:595–599.
   PubMed Web of Science ®Google Scholar
• CUTLER NR, CLAGHORN J, SRAMEK JJ et al.: Pilot study of MK-462 in migraine. Cephalalgia (1996) 16:113–116.
   PubMed Web of Science ®Google Scholar
• VISSER WH, TERWINDT GM, REINES SA, JIANG K, LINES CR, FERRARI MD, FOR THE DUTCH/US RIZATRIPTAN STUDY GROUP: Rizatriptan vs. sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch. Neural. (1997) 53:1132–1137.
   Google Scholar
• TEALL J, TUCHMANN M, CUTLER N etal. ON BEHALF OF THE RIZATRIPTAN 022 STUDY GROUP. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache (1998) 38:281–287.
   Google Scholar
• TFELT-HANSEN P, TEALL J, RODRIGUEZ F etal. ON BEHALF OF THE RIZATRIPTAN 030 STUDY GROUP: Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache (1998) 38:748–755.
   Google Scholar
• GOLDSTEIN J, RYAN R, JIANG K et al AND THE RIZATRIPTAN PROTOCOL 046 STUDY GROUP: Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. Headache (1998) 38:737–747.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, MATZURA-WOLFE D, POLIS A et al AND THE RIZATRIPTAN MULTIPLE ATTACK STUDY GROUP: A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology (1998) 51:773–781.
   PubMed Web of Science ®Google Scholar
• •A trial with an innovative way to assess the consistency of efficacy of a migraine drug across single migraine attacks.
   Google Scholar
• PASCUAL J, VEGA P, DIENER HC, ALLEN C, VRIJENS F, PATEL K AND THE RIZATRIPTAN-ZOLMITRIPTAN STUDY GROUP: Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia (2000) 20:455–461.
   Google Scholar
• BOMHOF M, PAZ J, LEGG N, ALLEN C, VANDORMAEL K, PATEL K: Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur. Neural (1999) 42:173–179.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ: Rizatriptan in acute treatment of migraine: update on new comparative data. Cephalalgia (2000) 20\(Suppl. 1):10–15.
   Google Scholar
• AHRENS SP, FARMER MV, WILLIAMS DL et al. AND THE RIZATRIPTAN WAFER PROTOCOL 049 STUDY GROUP: Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia (1999) 19:525–530.
   PubMed Web of Science ®Google Scholar
• ADELMAN JU, MANNIX LK, SEGGERN VON RL: Rizatriptan tablet versus wafer: patient preference. Headache (2000) 40:371–372.
   PubMed Web of Science ®Google Scholar
• KLAPPERJA, O'CONNOR S: Rizatriptan wafer-sublingual vs. placebo at the onset of acute migraine. Cephalalgia (2000) 20:585–587.
   Google Scholar
• DIENER HC, MCHARG A.: Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. Int. Clirr. Pict. (2000) 54:670–674.
   Google Scholar
• FARKKILA M, DIENER HC, DAHLOF C, STEINER TJ, ON BEHALF OF THE ELETRIPTAN STEERING COMMITTEE: A dose-finding study of eletriptan (5-30 mg) for the acute treatment of migraine. Cephalalgia (1996) 16:387.
   Web of Science ®Google Scholar
• GOADSBY PJ, FERRARI MD, OLESEN J etal. FOR THE ELETRIPTAN STEERING COMMITTEE. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology (2000) 54:156–163.
   Google Scholar
• STEINER TJ, ON BEHALF OF THE ELETRIPTAN STEERING COMMITTEE: The efficacy, saftey and tolerability of oral eletriptan (40 mg and 80 mg) for the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel group clinical trial. Migraine Trust, London (1998).
   Google Scholar
• REECHES A, ON BEHALF OF THE ELETRIPTAN STEERING COMMITTEE: Comparison of the efficacy, safety and tolerability of oral eletriptan (RelpaxTM) and Cafergot for the acute treatment of migraine. Paper read at 9th Congress of the International Headache Society, at Barcelona (1999).
   Google Scholar
• CABARROCAS X, ZAYAS JM, ON BEHALF OF THE ALMOTRIPTAN ORAL STUDY GROUP: Efficacy data on oral almotriptan, a novel 5-HT1B/D agonist. Headache (1998) 38:377.
   Google Scholar
• PASCUAL J: Therapy with other triptans: almotriptan. In Drug Treatment of Migraine and Other Headaches, HC Diener (Ed.) Basel, Karger, Switzerland (2000).
   Google Scholar
• PASCUAL J, FALK RM, PIESSENS F et al.: Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia (2000) 20:588–596.
   PubMed Web of Science ®Google Scholar
• CABARROCAS X, ZAYAS JM, SURIS M,ON BEHALF OF THE ALMOTRIPTAN ORAL STUDY GROUP: Equivalent efficacy of oral almotriptan, a new 5-HT1B/ D agonist, compared with sumatriptan 100 mg. Headache (1998) 38:377–378.
   Google Scholar
• BROWN AM, HO M, THOMAS DR, PARSON AA: Comparison of functional effects of frovatriptan, sumatriptan and naratriptan on human recombinant 5-HT1 and 5-HT7 receptors. Headache (1998) 38:376.
   Google Scholar
• GOLDSTEIN J, ELKIND A, KEY WOOD C, KLAPPER J, RYAN R: A low dose range-finding study of frovatriptan: a potent selective 5-HT1B/D agonist for the acute treatment of migraine. Headache (1998) 38:382–383.
   Google Scholar
• THE INTERNATIONAL HEADACHE SOCIETY COMMITTEE ON CLINICAL TRIALS IN MIGRAINE: Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia (1991) 11:1–12.
   Web of Science ®Google Scholar
• PILGRIM AJ: Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur. Neural (1991) 31:295–299.
   PubMed Web of Science ®Google Scholar
• TFELT-HANSEN P: Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia (1998) 18:532–538.
   PubMed Web of Science ®Google Scholar
• FERRARI MD: The war of the triptans. In: EFNS Conference 1999. Lisbon, Portugal (1999).
   Google Scholar
• STARK S, SPIERINGS ELH, MCNIEL S, PUTNAM GP, BOLDEN-WATSON CP, 0 'QUINN S: Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache (2000) 40:513–520.
   PubMed Web of Science ®Google Scholar
• VISSER WH, JASPERS N, DE VRIEND RHM, FERRARI MD: Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia (1996) 16:264–269.
   PubMed Web of Science ®Google Scholar
• DIENER HC, TFELT-HANSEN P: Headache associated with chronic use of substances. In: The headaches. J Olesen, P Tfelt-Hansen & KMA Welch (Eds.) New York: Raven Press, USA (1993).
   Google Scholar
• KAUBE H, MAY A, DIENER HC, PFAFFENRATH V: Sumatriptan misuse in daily chronic headache. BMJ(1994) 308:1573.
   PubMed Web of Science ®Google Scholar
• GAIST D, HALLAS J, SINDRUP SH, GRAM LF: Is overuse of sumatriptan a problem? A population-based study. Eur. Clin. Pharmacy]. (1996) 3:161–165.
   Google Scholar
• GAIST D, TSIROPOULUS I, SINDRUP SH, HALLAS J, RASMUSSEN BK, KRAGSTRUP J: Inappropriate use of sumatriptan: population based register and interview study. Br j Med. (1998) 316:1352–1353.
   PubMed Web of Science ®Google Scholar
• GAIST D: Use and overuse of sumatriptan.Pharmaco-epidemiological studies based on prescription register and interview data. Cephalalgia (1999) 19:735–761.
   Google Scholar
• KATSARAVA Z, FRITSCHE G, DIENER HC, LIMMROTH V: Drug-induced headache (DIH) following the use of different triptans. Cephalalgia (2000) 20:293 (abstract).
   Google Scholar
• LIMMROTH V, KAZARAWA S, FRITSCHE G, DIENER HC: Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet (1999) 353:378.
   PubMed Web of Science ®Google Scholar
• •The first publication showing, that all triptans can induce mediaction overuse headache
   Google Scholar
• MAASSENVANDENBRINK A, REEKERS M, BAX WA, FERRARI MD, SAXENA PR: Coronary side-effect potential of current and prospective antimigraine drugs. Circulation (1998) 98:25–30.
   PubMed Web of Science ®Google Scholar
• ••Experimental work showing, that thevasoconstrictive action of the different triptans at isolated human coronary arteries is almost identical.
   Google Scholar
• MASSENVANDENBRINK A, BAX WA, RAMRATTAN NN, FERRARI MD, SAXENA PR: Human isolated coronary artery contraction to sumatriptan: a post hoc analysis. Cephalagia (1999) 19:651–654.
   PubMed Web of Science ®Google Scholar
• CADY RK, LIPTON RB, HALL C, STEWART WF, O'QUINN S, GUTTERMAN D: Treatment of mild headache in disabled migraine sufferers: results of the Spectrum study. Headache (2001) 40:792–797.
   Web of Science ®Google Scholar
• DIENER HC, FOR THE RPR100893-201 MIGRAINE STUDY GROUP: Substance P antagonist RPR100893-201 is not effective in human migraine attacks. 6th International Headache Research Seminar, Copenhagen (1995):245–371.
   Google Scholar
• GOLDSTEIN DJ, WANG 0, SAPER JR, STOLTZ R, SILBERSTEIN ST, MATHEW NT: Ineffectiveness of neurokinin-1 antagonist in acute migraine: crossover study. Cephalalgia (1997) 17:785–790.
   PubMed Web of Science ®Google Scholar
• MAY A, GIJSMAN HJ, WALLNOFER A, JONES R, DIENER HC, FERRARI MD: Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain (1996) 67:375–378.
   PubMed Web of Science ®Google Scholar
• LASSEN LH, ASHINA M, CHRISTIANSEN I etal.: Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia (1998) 18:27–32.
   Google Scholar
• RAMADAN N, SANG C, CHAPPELL A et al: IV LY293558, an AMPA/KA receptor antagonist, is effective in migraine. Cephalalgia (2001) 21:267.
   Google Scholar
• PHEBUS LA, JOHNSON KW, ZGOMBICK JL et al.: Characterization of LY334370 as a pharmacological tool to study 5HT1F receptors binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1(1997) 61:2117-2126.
   Google Scholar
• LIPTON RB, STEWART WF, RYAN RE, SAPER J, SILBERSTEIN S, SHEFTELL F: Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain - Three double-blind, randomized, placebo-controlled trials. Arch. Neural. (1998) 55:210–217.
   PubMed Web of Science ®Google Scholar
• MYLLYLA VV, HAVANKA H, HERRALA L et al: Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, prallel-group study. Headache (1998) 38:201–207.
   PubMed Web of Science ®Google Scholar
• TFELT-HANSEN P, HENRY P, MULDER LJ, SCHAELDEWAERT RG, SCHOENEN J, CHAZOT G: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet (1995) 346:923–926.
   PubMed Web of Science ®Google Scholar
• DE CRAEN AJM, TIJSSEN JGP, DE GANS J, KLEIJNEN J: Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. j Neural. (2000) 247:183–188.
   PubMed Web of Science ®Google Scholar
• MCQUAY H, CARROLL D, MOORE A: Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain (1995) 64:331–335.
   Web of Science ®Google Scholar
• MIGRAINE-NIMODIPINE EUROPEAN STUDY GROUP M: European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache (1989) 29:633–638.
   PubMed Web of Science ®Google Scholar
• MIGRAINE-NIMODIPINE EUROPEAN STUDY GROUP M: European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache (1989) 29:639–642.
   PubMed Web of Science ®Google Scholar
• COUCH JR: Placebo effect and clinical trials in migraine therapy. Neuraepidemialogy (1987) 6:178–185.
   PubMed Web of Science ®Google Scholar
• RABKIN R, STABLES DP, LEVIN NW, SUZMAN MM: The prophylactic value of propranolol in angina pectoris. Am. Cardial (1966) 18:370–383.
   PubMed Web of Science ®Google Scholar
• HOLROYD KA, PENZIEN DB, CORDINGLEY GE: Propranolol in the management of recurrent migraine: a meta- analytic review. Headache (1991) 31:333–340.
   PubMed Web of Science ®Google Scholar
• KANGASNIEMI P, HEDMAN C: Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia (1984) 4:91–96.
   PubMed Web of Science ®Google Scholar
• LJUNG 0: Treatment of migraine with metoprolol. N Engl. I Med. (1980) 303(3):664–668.
   PubMedGoogle Scholar
• STEINER TJ, JOSEPH R, HEDMAN C, CLIFFORD ROSE F: Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. Headache (1988) 28:15–23.
   PubMed Web of Science ®Google Scholar
• OLSSON JE, BEHRING HC, FORSSMAN B etal.: Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. Acta Neural Land. (1984) 70:160–168.
   Google Scholar
• SORENSEN PS, AND THE DANISH MIGRAINE STUDY GROUP: Prophylactic effect of flunarizine versus metoprolol in migraine. Cephalalgia (1989) 9:355–356.
   Google Scholar
• SORENSEN PS, LARSEN BH, RASMUSSEN MJK etal.: Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache (1991) 31:650–657.
   Google Scholar
• VILMING S, STANDNES B, HEDMAN C: Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double-blind investigation. Cephalalgia (1985) 5:17–23.
   PubMed Web of Science ®Google Scholar
• WORZ R, REINHARDT-BENMALEK B, GROTEMEYER KH, FOH M: Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura - a randomized double-blind cross-over multicenter study. Cephalalgia (1991) 11\(Suppl. 11):152–153.
   Google Scholar
• GAWEL MJ, KREEFT J, NELSON RF, SIMARD D, ARNOTT WS: Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can. j Neural Sci. (1992) 19:340–345.
   PubMed Web of Science ®Google Scholar
• HOLROYD KA, PENZIEN DB, ROKICKI LA, CORDINGLEY GE: Flunarizine vs. propranolol: a meta-analysis of clinical trials. Headache (1992) 32: 256.
   Google Scholar
• LUDIN H-P: Flunarizine and propranolol in the treatment of migraine. Headache (1989) 29:218–223.
   Google Scholar
• LOCKING CH, OESTREICH W, SCHMIDT R, SOYKA D: Flunarizine vs. propranolol in the prophylaxis of migraine: Two double-blind comparative studies in more than 400 patients. Cephalalgia (1988) 8:21–26.
   Google Scholar
• SHIMELL CJ, FRITZ VU, LEVIEN SL: A comparative trial of flunarizine and propranolol in the prevention of migraine. S. Air Med. j (1990) 77:75–78.
   PubMed Web of Science ®Google Scholar
• FORSSMAN B, LINDBLAD CJ, ZBORNIKOVA V: Atenolol for migraine prophylaxis. Headache (1983) 23:188–190.
   PubMed Web of Science ®Google Scholar
• STENSRUD E SJAASTAD 0: Comparative trial of Tenormin (atenolol) and Indere' (propranolol) in migraine. Headache (1980) 20:204–207.
   PubMed Web of Science ®Google Scholar
• BRIGGS RS, MILLAC PA: Timolol in migraine prophylaxis. Headache (1979) 19:379–381.
   PubMed Web of Science ®Google Scholar
• STELLAR S, AHRENS S, MEIBOHM AR, REINES AS: Migraine prevention with timolol. A double-blind crossover study. JAMA (1984) 252:2576–2580.
   Google Scholar
• TFELT-HANSEN E STANDNES B, KANGASNIEMI E HAKKARAINEN H, OLESEN J: Timolol vs. propranolol vs. placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neural Scalar/. (1984) 69:1–8.
   Google Scholar
• FREITAG FG, DIAMOND S: Nadolol and placebo comparison study in the prophylactic treatment of migraine. j Am. Osteopath. Assoc. (1984) 84:343–347.
   PubMed Web of Science ®Google Scholar
• VAN DE VEN LLM, FRANKE CL, KOEHLER PJ, ON BEHALF OF THE INVESTIGATORS: Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia (1997) 17:596–599.
   PubMed Web of Science ®Google Scholar
• OLESEN J, TFELT-HANSEN P, WELCH KMA. The headaches 2. Raven Press, New York, USA (1998).
   Google Scholar
• ••The most important textbook on the diagnosis and treatment of headache.
   Google Scholar
• NIKOLOV R, DIKOVA M, PETKOV 0, NIKOLOVA M: XLI-8 Flunarizine prevents the endothelin-impaired cerebral resistance to hypoxia and local cerebral blood flow. j Cereb. Blood Flow Metab. (1991) 11:71422:379–382.
   Google Scholar
• DIENER HC: Flunarizine for migraine prophylaxis. In Drug treatment of migraine and other headaches. HC Diener (Ed.) Karger, Basel, Switzerland.
   Google Scholar
• MARKLEY HG, CHERONIS CD, PIEPHO RW: Verapamil in prophylactic therapy of migraine. Neurology (1984) 34:973–976.
   PubMed Web of Science ®Google Scholar
• SOLOMON CGD, STEEL MJG, SPACCAVENTO CU: Verapamil prophylaxis of migraine. JAMA (1983) 250:2500–2502.
   PubMed Web of Science ®Google Scholar
• SCHOLZ E, GERBER WD, DIENER HC, LANGOHR HD, REINECKE M: Dihydroergotamine versus flunarizine versus nifedipine versus metoprolol versus propranolol in migraine prophylaxis. A comparative study based on time series analysis. In: Advances in Headache Research. Clifford Rose (Ed). John Libey & Co. London, UK (1987).
   Google Scholar
• ALBERS GW, SIMON LT, HAMIK A, PEROUTKA SJ: Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache (1989) 29:214–217.
   Google Scholar
• NEUMANN M, DEMAREZ JP, HARMEY JL, LE BASTARD B, CAUQUIL J: Prevention of migraine attacks through the use of dihydroergotamine. mt. I Chit. Pharm. Res. (1986) 6:11–13.
   Google Scholar
• GROTEMEYER K-H, SCHLAKE H-P, HUSSTEDT IW: Etilefrine pivalate vs. dihydroergotamin and flunarizin in prophylactic treatment of migraine in patients with low blood pressure - A randomized double-blind-study. Cephalalgia (1989) 9:433–434.
   Google Scholar
• SILBERSTEIN SD. Methysergide. Cephalalgia (1998) 18:421–435.
   PubMed Web of Science ®Google Scholar
• BURING JE, PETO R, HENNEKENS CH. Low-dose aspirin for migraine prophylaxis. JAMA (1990) 264:1711–1713.
   Google Scholar
• GROTEMEYER K, SCHARAFINSKI H, SCHLAKE H, HUSSTEDT IW: Acetylsalicylic acid vs. metoprolol in migraine prophylaxis - a double blind cross-over study. Headache (1990) 30:639–641.
   Google Scholar
• DIENER HC, HARTUNG E, CHRUBASIK J et al. ON BEHALF OF THE STUDY GROUP: Acetylsalicylic acid in migraine prophylaxis: a double blind study in comparison with metoprolol. Paper read at 8th Congress of the International Headache Society, Amsterdam, The Netherlands (1997).
   Google Scholar
• ZIEGLER DK, ELLIS DJ: Naproxen in prophylaxis of migraine. Arch. Neural (1985) 42:582–584.
   PubMed Web of Science ®Google Scholar
• BEHAN PO, CONNELLY K: Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache (1986) 26:237–239.
   PubMed Web of Science ®Google Scholar
• BELLAVANCE AJ, MELOCHE JP: Comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache (1990) 30:710–715.
   PubMed Web of Science ®Google Scholar
• SARGENT J, SOLBACH P, DAMASIO H et al.: A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache (1985) 25:320–324.
   PubMed Web of Science ®Google Scholar
• SANCES G, MARTIGNONI E, FIORONI L, BLANDINI F, FACCHINETTI F, NAPPI G: Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache (1990) 30:705–709.
   PubMed Web of Science ®Google Scholar
• DIAMOND S, FREITAG FG, GALLAGHER RIVI, FEINBERG DT: Ketoprofen in the prophylaxis of migraine. Headache Quarterly (1990) 1:75–77.
   Google Scholar
• JOHNSON RH, HORNABROOK RW, LAMBIE DG: Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neural Scand. (1986) 73:490–492.
   PubMed Web of Science ®Google Scholar
• MIKKELSEN B, PEDERSEN KK, CHRISTIANSEN LV: Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neural Land. (1986) 73:423–427.
   PubMed Web of Science ®Google Scholar
• COUCH JR, HASSANEIN RS: Amitriptyline in migraine prophylaxis. Arch. Neural (1979) 36:695–699.
   PubMed Web of Science ®Google Scholar
• ZIEGLER DK, HURWITZ A, HASSANEIN RS: Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch. Neural (1987) 44:486–489.
   PubMed Web of Science ®Google Scholar
• ZIEGLER DK, HURWITZ A, PRESKORN S, HASSANEIN R, SEIM J: Propranolol and amitriptyline in prophylaxis of migraine. Arch. Neural (1993) 50:825–830.
   PubMed Web of Science ®Google Scholar
• BUSSONE G, CERBO R, MARTUCCI N et al.: Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. Headache (1999) 39:426–431.
   PubMed Web of Science ®Google Scholar
• PEIKERT A, WILIMZIG C, KOHNE-VOLLAND R: Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia (1996) 16:257–263.
   PubMed Web of Science ®Google Scholar
• PFAFFENRATH V, WESSELY P, MEYER C et al: Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. Cephalalgia (1996) 16:436–440.
   PubMed Web of Science ®Google Scholar
• SCHOENEN J, LENAERTS M, BASTINGS E: High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia (1994) 14:328–330.
   PubMed Web of Science ®Google Scholar
• SCHOENEN J, JACQUY J, LENAERTS M: High-dose power riboflavin as a novel prophylactic antimigraine therapy: results from a double-blind, randomized, placebo-controlled trial. Cephalalgia (1997) 17:244.
   Google Scholar
• SILBERSTEIN S, MATHEW N, SAPER J, JENKINS S, FOR THE BOTOX MIGRAINE CLINICAL RESEARCH GROUP: Botulinum toxin type A as a migraine preventive treatment. Headache (2000) 40:445–450.
   PubMed Web of Science ®Google Scholar
• HERING R, KURZITZKY A: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia (1992) 12:81–84.
   PubMed Web of Science ®Google Scholar
• JENSEN R, BRINCK T, OLESEN J: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology (1994) 44:647–651.
   PubMed Web of Science ®Google Scholar
• KANIECKI RG: A comparision of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch. Neural. (1997) 54:1141–1145.
   PubMed Web of Science ®Google Scholar
• KLAPPER J, ON BEHALF OF THE DIVALPROEX SODIUM IN MIGRAINE PROPHYLAXIS STUDY GROUP: Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia (1997) 17:103–108.
   PubMed Web of Science ®Google Scholar
• MATHEW NT, SAPER JR, SILBERSTEIN SD et al.: Migraine prophylaxis with divalproex. Arch. Neural. (1995) 52:281–286.
   PubMed Web of Science ®Google Scholar
• STEINER TJ, FINDLEY LJ, YUEN AWC: Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia (1997) 17:109–112.
   PubMed Web of Science ®Google Scholar
• LAMPL C, BUZATH A, KLINGER D, NEUMANN K: Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. Cephalalgia (1999) 19:58–63.
   PubMed Web of Science ®Google Scholar
• MATHEW NT, RAPOPORT A, SAPER J, MAGNUS L, KLAPPER J, RAMADAN N, STACEY B, TEPPER S: Efficacy of gabapentin in migraine prophylaxis. Headache (2001) 41:119–128.
   PubMed Web of Science ®Google Scholar
• NEWMAN LC, LIPTON RB, LAY CL, SOLOMON S: A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology (1998) 51:307–309.
   PubMed Web of Science ®Google Scholar
• PRADALIER A, VINCENT D, BEAULIEU PH, BAUDESSON G, LAUNAY JM: Correlation between between oestradiol plasma level and therapeutic effect on menstrual migraine. In: New advances in headache research. F Clifford-Rose (Ed.) Smith-Gordon London, UK (1994).
   Google Scholar
• HERSHEY AD, POWERS SW, BENTTI AL, GRAM DE TJ: Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache (2000) 40:539–549.
   PubMed Web of Science ®Google Scholar
• LANZI G, BALOTTIN U, ZAMBRINO CA et al: Guidelines and recommendations for the treatment of migraine in pediatric and adolescent patients. Funct. Neural (1996) 11:269–275.
   PubMed Web of Science ®Google Scholar